Treatment strategies in Endoprosthesis with documented infection.

Original title: A 14-years Experience with Aortic Endograft Infection: Managemente and Results. Reference: O.T.A. Lyons, et al. European Journal of Vascular and Endovascular Surgery 46;3:306-313

 

The infection of an Endoprosthesis is a rather infrequent complication, undesirable and associated with poor evolution, with little information in the literature and an unclear treatment strategy.

Traditionally, the prosthesis infection has been treated by prosthesis removal, debridement of all the infected tissue and artery reconstruction followed by long antibiotic therapy.  However, such a surgery in patients that were poor candidates from the onset, reached a mortality rate of around 30% for the abdominal prosthesis and even higher for thoracic prosthesis.

This work involves a series of 22 consecutive patients (13 abdominal and 9 thoracic) with a documented prosthesis infection treated between 1998 and 2012.Of the total, 7 patients (32%) were given Endoprosthesis to treat complications of a previous conventional surgery. During the duration of the study, 7 aortoenteric fistulae post conventional surgery were treated with Endoprosthesis, 6 of which (86%) became infected. The infection occurred within an average of 5 months (0-51) from the implant, being the most important risk factors post implant septicemia, primary infectious, re-interventions and the fistulae. From those who presented devices in the abdominal aorta, 11 received aspiration puncture, 3 were not considered for invasive treatment due to their physical condition and died. The remaining 10 had the prosthesis removed (3 of these died within 30 days). In the medium term monitoring 3 more deaths occurred, 2 of which were not related to the Endoprosthesis infection. The prosthesis was not removed in any of the 9 patients with devices in the thoracic aorta.  

An aspiration puncture was performed in 3, and a new prosthesis implanted due to the risk of bleeding or progress of the pseudo-aneurism in another 3. There were no deaths within 30 days but in the monitoring of the next 2 years, 7 out of 9 were dead.

Conclusion:

The removal of an infected abdominal Endoprosthesis results in high mortality and morbidity however it can be curative. The selection of candidates to the removal remains a big challenge. The conservative handling of an infected aortic Endoprosthesis can be associated with a survival rate not greater than 2 years. 

Comments:

An infection in prosthesis is infrequent posing a true challenge to its solution. There is little information about this issue but all of them coincide that it gives a negative prognosis.

Many patients are not candidates for the removal; besides, the reconstructive surgery and the extra anatomic bypass also present a high morbimortality rate. The aspiration drainage reduces or prevents the septicemia but has little influence on the final result.

Contribution Dr Carlos Fava.
Interventional Cardiologist.
Favaloro Foundation. Argentina.

Dr. Carlos Fava para SOLACI.ORG

More articles by this author

ACC 2026 | HI-PEITHO: Catheter-directed strategy (EKOS) in intermediate-risk acute pulmonary embolism

The treatment of intermediate-risk pulmonary embolism (PE) continues to be an area of therapeutic uncertainty. The initial PEITHO study (2014) demonstrated a reduction in...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...

AHA/ACC Guideline on the Management of Acute Pulmonary Embolism 2026

The 2026 ACC/AHA guideline for the management of acute pulmonary embolism (PE) introduces a conceptual shift by replacing the traditional “risk-based” classification with an...

FFR Assessment for the Selection of Hypertensive Patients Who Benefit from Renal Stenting

Atherosclerotic renal artery stenosis (ARAS) represents one of the main causes of secondary hypertension (HTN) and is associated with a higher risk of renal...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio

Coronary physiological assessment using pressure-wire techniques (FFR/iFR) carries a Class IA recommendation in ACC/AHA guidelines; however, its use remains limited due to factors such...

ACC 2026 | Protect The Head-To-Head Trial: Randomized Comparison Between Emboliner and Sentinel During TAVI

Ischemic stroke remains one of the most feared complications of TAVI, with a relatively low but persistent incidence of 2–4%, without significant reduction over...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...